Summary Timing of surgery in premenopausal patients with breast cancer remains controversial. Angiogenesis is essential for tumour growth and vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. We aimed to determine whether the study of VEGF in relation to the menstrual cycle could help further the understanding of this issue of surgical intervention. Fourteen premenopausal women were recruited, along with three post-menopausal women, a woman on an oral contraceptive pill and a single male subject. Between eight and 11 samples were taken per person, over one menstrual cycle (over 1 month in the five controls) and analysed for sex hormones and VEGF165. Serum VEGF was significantly lower in the luteal phase and showed a significant negative correlation with progesterone in all 14 premenopausal women. No inter-sample variations of VEGF were noted in the controls. Serum from both phases of the cycle from one subject was added to MCF-7 breast cancer cells; VEGF expression in the supematant was lower in the cells to which the luteal phase serum was added. The lowering of a potent angiogenic cytokine in the luteal phase suggests a possible decreased potential for micrometastasis establishment in that phase. This fall in VEGF may be an effect of progesterone and should be the focus of future studies.
TIhe controversy of the timing of surgical intervention in premenopausal breast cancer patients was initiated when Hrushesky et al (1989) . in a study of 44 patients. observed a better survival for tumours resected between days 7 and 20 of the menstrual cycle.
Various studies follox%ed. with differing results. though four major studies have favoured the second half of the cycle. when the influence of progesterone predominates (Badwe et al. 1991; Senie et al. 1991 : Veronesi et al. 1994 : Goldhirsch et al. 1997 .
Angiogenesis has been shown to be essential for both the growth and metastasis of many solid tumours. with a large number of the data resulting from studies of breast cancer. In the absence of angiogenesis. a tumour will not grow beyond the size of 2-3 mm (Gimbrone et al. 1972) . Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic cytokines. for both normal embryogenesis and tumour growth (Breoer et al. 1990 : Kim et al. 1993 . Breast tumour VEGF directly correlates with intratumoral micros essel density and. furthermore. has been shown to be an independent indicator of nodal metastasis and disease-free sunival (Toi et al. 1994) .
Because VEGF plays an important role in tumour growth. we aimed to determine whether the study of this cytokine in premenopausal women could identify variations of VEGF within the normal menstrual cycle and. thus. suggest why the timing of surgery might influence the outcome of breast cancer. Received 15 December 1997 Revised 25 March 1998 Accepted 7 April 1998 Correspondence to: MJ Kenn. Academic Surgical Unit, University of Hull.
Castle Hill Hospital, Cotlingham. East Yorkshire HU16 5JQ, UK 
MATERIALS AND METHODS
Fourteen premenopausal women were recruited with no prior history of any breast disorders. None had any significant medical history. except one woman, who had ankylosing spondylosis.
Three groups of controls were included: three post-menopausal women. one premenopausal woman on a low-dose oestrogen combined oral contraceptive pill and one male subject. Informed verbal consent was obtained from all subjects.
Blood samples were taken at 4-day intervals in both the subjects and the controls. In the case of the premenopausal women, these were taken from day 1 of one menstrual cycle through to day 1 of the following cycle (8-11 samples per person). Two extra periovulatory samples were taken in four premenopausal women: thus. a total of 123 samples were taken from the premenopausal women. 65 in the follicular phase and 58 in the luteal phase. The controls had samples taken over a period of 1 month on the following days -1. 5. 9. 13. 17. 21. 25 and 29 (eight samples per control): thus. a total of 40 control samples were obtained from the five controls. The serum was separated and stored at -80°C and thawing was avoided until the assays were performed.
Simultaneous quantitative enzyme-hinked immunosorbent assays (ELISAs) were performed for VEGF165 (R&D. UK). follicle-stimulating hormone (FSH). luteinizing hormone (LH) and progesterone (AxSYM system. Abbott Laboratories. USA). Oestradiol was measured by radioimmunoassay (Coat-a-coat. Diagnostic Products Corporation. USA).
Each menstrual cycle was divided into a follicular phase and a luteal phase on the basis of an observed LH peak followed by a progesterone level that fell within the luteal phase values of the system used (. 10.4 nmol 1-1). (-0.193) The sianificance between VEGF. oestradiol and progesterone levels of the tx% o phases for all cycles was calculated using the Mann-Whitney U-test for non-parametric data. Spearman's correlation between these three variables was also calculated. A oneway ANOVA (analysis of variance) was performed on the controls. Serum from the follicular and luteal phases of the cycle of one subject were each added in 5%7c concentration on two occasions to a triplicate group of wells. Two sets of serum taken approximately 2 weeks apart from the control subject on the oral contraceptive pill were also added to two sets of wells. After 4 days of growth. the resultant supernatant was collected from each of the 12 wells and assayed for VEGF165 by quantitative ELISA.
RESULTS
The menstrual cycles ranged from 26 to 35 days in length (median 28 days). AH cycles were found to be ov-ulatoryv that is. each showed an LH surge followed by an appropriate mid-luteal peak of progesterone (>16.7 nmol 1-1. reference range of AxSYM system).
VEGF levels in the luteal phase (median 174.7 pg ml') were significantly lower than those of the follicular phase (median 206.5 pg ml-'). with a P-value of 0.03 at 95% significance lesel. (Table 1 . Figure 1 ). The fall of VEGF between the peaks of the follicular and luteal phases in each subject was calculated. This showed an average fall of 53.2% for all cycles taken together with a ranae of 35.4-81.7%c.
Progyesterone levels were significantly higher in the luteal phase than the follicular phase (P < 0.0005). which was consistent with the expected normal ovulatory luteal function. A corresponding significant negative correlation was found betxeen VEGF and progesterone (P = 0.03). Oestradiol levels did not vary significantly between the two phases (P = 0.6). though the follicular phase levels were marginally higher. Again. these values corresponded to the expected range of oestradiol in o-ulatory cycles.
Spearman's correlation showed no significance between VEGF and oestradiol (P = 0.37) ( Table 1) . A one-w ay ANOVA was performed on the 40 control samples to detenrine whether any statistical significance existed among the day-to-day levels of the three factors. i.e. oestradiol. progesterone and VEGF. This revealed no significant difference within the groups for VEGF. oestradiol or progesterone on the sample days. with P-values of 1.0. 0.99 and 0.86 respectively. Fiaure 2 represents the graph of a post-menopausal control.
On redefining the cycles on the basis of the median day of establishment of the luteal phase as described. VEGF levels in the luteal' phase (i.e. values from day 17 onwards) were significantly lower than in the 'follicular' phase (values from day 1 to 16). The median luteal' level was 171.9 pg ml-' (IQR 82.7-225.0) compared with a median follicular' level of 215.6 pg ml.' (IQR 121 .1-238. 1). P = 0.009 (Mann-Whitney U-test).
Analysis of the supematant from the MCF-7 breast cancer cells grown with serum from a subject and a control showed that the VEGF levels in the wells to which serum from the luteal phase was added were significantly low er than the levels from the cells grown in serum from the follicular phase (mean VEGF of three samples with luteal serum: 706.73 pg ml-': mean VEGF of samples with follicular serum: 800.04 pg ml-l: P = 0.05. Mann-Whitney U-test).
The supematant from the wells to which control serum had been added did not show any significant difference in VEGF expression (mean VEGF: 638.06 p mlF vs. 634.11 pg ml-': P = 0.5 .
Britsh Joumal of Cancer (1998) (Pertovaaraetal, 1994; (interleukin 6, interleuk al, 1995; Li et al, 1995 (ras, v-raf, v-Srr) (Grul Rak et al, 1995 al, 1995; Mukhopadhyay et al, 1995;  did not show variations in oestradiol or progesterone levels did not ias led to the belief that VEGF, acting in a result in any variations in VEGF expression. These findings be the fmal common pathway of unconprovide firther evidence that it is probably the high progesterone tion (Ferrara, 1996) . levels in the luteal phase that decrease VEGF expression. shown that heterozygous mutations of the VEGF, being induced by inflammatory mediators, is known to et al, 1996) and homozygous mutations of rise in conditions such as autoimmune arnhritis. This was reflected 995) or KDR (Shalabi et al, 1995) genes in the generally higher levels of VEGF seen in the subject who had mne death, demonstrating the indispensexacerbation of ankylosing spondylosis during the cycle of this EGF receptor system for normal developstudy, compared with the rest of the study group (median 533.3 vs. stem.
175.6 pg ml-', P < 0.0005, Mann-Whitney test): but, even in this shown that serum VEGF is elevated with subject, VEGF fell significantly during the luteal phase, only to )rectal cancer (Kumar et al. 1998) and that rise sharply once progesterone levels returned to baseline values. vels can predict oncological clearance.
The three groups of controls were chosen for two reasons: firstly VEGF in tunmofigenesis and inflammatory to determine whether serum VEGF ordinarily showed daily fluctuLsingly studied and understood, the signifiations in a population that excluded premenopausal women and. GF in the healthy adult remains to be estabsecondly, if not, whether the variations in premenopausal women is believed that VEGF may have a role in could be attributed to hormonal variations, as these three control y of the vascular endothelium (Jakeman et groups would not be expected to show any significant day-to-day g a rather quiescent epithelium in the adult, changes in their hormonal profile. Indeed. as expected, no signifiiations in serum VEGF would be expected cant fluctuations in oestradiol or progesterone levels were noted, Ferrara et al ( 1991 ) was detected (P = 1.0). This corroborated the evidence that the VEGF changes in premenopausal women were probably hormone dependent. In addition. serum VEGF in the three post-menopausal wAomen was higher than in the premenopausal women. This was as suggested in an earlier studv from our unit on 138 healthy controls from the general population (66 men and 72 women). This studv had shown that there was no significant difference between VEGF levels in men (median 171.4 pg ml-') compared with those in females (median 173.8 pg ml-': P = 0.99): however. there was a sig,nificant difference between premenopausal (n = 52. median VEGF 165 pg ml-') and post-menopausal women (n = 20. median VEGF 243.9 pg ml: P = 0.01). No such difference was found between the VEGF levels in males when a cut-off point of 50 years (average agye of menopause) was used. i.e. men <50 years (n = 44. median VEGF = 171.4 pg ml-') compared with men > 50 years (n = 22. median VEGF = 179.1 pg, ml-l' P = 0.89) ( Table 2 ). These data emphasize the point that the changes found in women are unlikely to be attributable to a difference in age.
In a retrospective study. Badwe et al (1991) Folkman (1995) suggaests that the presentation of metastases is dictated by the intensitv of angiogenesis that they induce. Once the balance of negative and positive angliogenesis factors is such that proangiogenic factors predominate. the micrometastases switch to the angiogenic phenotype and grow.
VEGF is one of the key factors secreted by the tumour implicated in the local micrometastasis milieu. It has been experimentally shown that the administration of anti-VEGF antibodies and the introduction of dominant negative VEGF receptors (to interfere with VEGF signalling) result in reduction of tumour growth (Millauer et al. 1994 : Warren et al. 1995 . Also. anti-VEGF antibodies inhibit the development of metastasis even when the size of the primary is similar to that of untreated animals with metastasis (Melnyk et al. 1996) and serum VEGF is reduced following tumour removal. suggesting that VEGF might function as an endocrine endothelial factor in some populations of patients (Yamamoto et al. 1996 : Kumar et al. 1997 ).
Folkman's view of micrometastasis is now widely, accepted. though in the context of breast cancer the contribution of the sexual hormonal profile remains controversial. We believe that VEGF expression may provide that link. The stimulatory role of oestrogen in normal and neoplastic breast tissue has been shown in multiple in vitro and in vi-omodels. It has also been shown that oestradiol causes up-regaulation of VEGF expression in human endometrial cancer cell lines (Chamnock-Jones et al. 1993) . and that the pattern of expression of VEGF suggtests that it plays a role in hormone-regulated anglogenesis (Shwveiki et al. 1993 ). Our present in vivo and in vitro results indicate that progesterone may be the factor causing down-regulation of VEGF Thus. the findinc of a lower serum VEGF in the luteal phase would support both Badwe's findings and Folkman's anaiogenesis hypothesis by creating a lower potential for angiogenesis. and. thus. for establishment of metastases in this phase. It is possible that the high levels of VEGF in post-menopausal women are a reflection of this protective effect of progesterone. i.e. even though there is insignificant ovarian oestradiol produced post-menopausually: it may be that even low levels of circulatincg extraovarian oestrogens. in the absence of any significant progesterone. are able to accumulate in an unopposed manner. resulting, in higher levels of serum VEGE This is a factor that may be worth further study in the context of the higher incidence of breast cancer in post-menopausal women.
By dividing each cycle on the basis of actual hormonal measurements. we have removed the bias as to which phase the recorded VEGF values belona. Interestingly, when the cycles were divided on the basis of a median dav of establishment of the luteal phase. the drop in levels of VEGF in the second half of the cycle became more significant. This was so even though the women had a wide ranae of individual cycle lengths. If further studies were to support luteal phase intervention on the basis of VEGF levels, then this finding, would potentially preclude the need to routinely perform preoperative hormone profiles. as surgery undertaken beyond day 17 could be considered as being within a 'safe' period of the cycle.
We have suggested a possible mechanism via which the improved prognosis of breast cancer surgery in the luteal phase may be explained. Further prospective clinical studies lookincg at the effects of oestrogen and progesterone on VEGF expression are required to establish progesterone as the protective factor. This would have immense implications not only in timing, surgical intervention in premenopausal breast cancer patients. but also in advancing the therapeutic options available for the disease.
